Merck & Co., Inc.

The transcript on page 7 and surrounding pages does not mention any current or planned fundraising activities through debt or equity issuance. Key points related to financing include: - No references to new debt or equity offerings in the discussion. - Focus is on executing business development and product launches. - Emphasis on growth from existing operations and pipeline advancements. - No indications of capital raising or financing needs disclosed during the Q1 2024 earnings call. Therefore, based on the provided transcript pages, Merck has not announced any current or future plans for fundraising through debt or equity.

- Merck remains committed to investing appropriately to realize the promise of its expansive early and late-phase pipeline. - Strategic investments focus on promoting key growth drivers and advancing innovative pipeline candidates. - Continued investment in innovative pipeline includes multiple novel candidates addressing important unmet medical needs. - Business development remains a priority to add compelling science through value-enhancing transactions. - Ample capacity supported by strong investment-grade credit rating and cash flow to pursue significant transactions. - The company prioritizes investments to drive near- and long-term growth. - Capital allocation strategy emphasizes executing external business development for value creation. - Investment in broad research efforts spans oncology, vaccines, HIV, and pulmonary arterial hypertension. - Ongoing clinical and commercial execution reflects commitment to innovation-driven growth.

- Merck raised and narrowed 2024 full-year revenue guidance to $63.7 billion - $64.3 billion, reflecting 5%-7% year-over-year growth despite foreign exchange headwinds. - Strong performance driven by KEYTRUDA, GARDASIL, and new product launches like Wind River. - KEYTRUDA sales grew 24% in Q1 2024, with expansions in earlier-stage cancers and metastatic indications expected to continue driving growth. - GARDASIL growth is sustained by ongoing global demand and plans for broader multivalent HPV vaccines to extend protection and market penetration. - Launch of Wind River, a new PAH treatment, exemplifies potential incremental revenue from novel therapies. - Continued investments in pipeline and business development expected to fuel medium- and long-term growth. - Focus on expanding delivery options such as subcutaneous KEYTRUDA may increase patient uptake and market size. - Overall, Merck expects a diversified and sustainable set of growth drivers through 2028 and beyond, with confidence in post-LOE recovery.

- Merck raised and narrowed its full-year 2024 revenue guidance to $63.6 billion - $64.3 billion, reflecting 5-7% growth year-over-year, despite foreign exchange headwinds. - EPS guidance increased and narrowed to a range of $8.53 to $8.65, incorporating approximately a $0.05 negative impact from foreign exchange. - Gross margin expected around 81%, with operating expenses between $25.2 billion and $26.1 billion. - Operating expenses decreased 4% YoY in Q1, partly due to reduced business development transaction charges. - Continued investment in innovation and pipeline support confidence in sustainable growth drivers beyond 2028. - CEO highlighted strong pipeline execution, commercial momentum, and manufacturing capabilities as key growth enablers. - Post-LOE (expiry of exclusivity) in 2028 seen more as a "hill" than a "cliff," with confidence in fast growth recovery beyond 2030. - Business development remains a priority to supplement internal innovation for long-term value.

The provided transcript pages do not specifically mention details about Merck's current or expected orderbook or pending orders. The focus is primarily on: - Product launches and pipeline progress (e.g., Wind River, RSV antibody clasrovumab, personalized cancer vaccine). - Sales growth of key brands (KEYTRUDA, GARDASIL, VAXNEUVANCE). - Market execution, business development strategy, and commercial uptake. - Manufacturing capacity and access programs. - Clinical pipeline updates and strategic outlook through 2028-2030. No explicit data or figures related to current or expected orderbooks or pending orders were disclosed in the discussed Q&A excerpts or prepared remarks.